Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;11(4):629-40.
doi: 10.2217/fon.14.279.

Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer

Luisa Foltran  1 , Giovanna De Maglio, Nicoletta Pella, Paola Ermacora, Giuseppe Aprile, Elena Masiero, Mariella Giovannoni, Emiliana Iaiza, Giovanni Gerardo Cardellino, Stefania Eufemia Lutrino, Micol Mazzer, Manuela Giangreco, Federica Edith Pisa, Stefano Pizzolitto, Gianpiero Fasola
Affiliations

Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer

Luisa Foltran et al. Future Oncol. 2015.

Abstract

Aim: To explore the prognostic value of extended mutational profiling for metastatic colorectal cancer (mCRC).

Materials & methods: We retrospectively reviewed survival results of 194 mCRC patients that were assigned to four molecular subgroups: BRAF mutated; KRAS mutated codons 12-13 only; any of KRAS codons 61-146, PIK3CA or NRAS mutations and all wild-type. Point mutations were investigated by pyrosequencing.

Results: BRAF (5.2%) and KRAS 12-13 (31.9%) mutations were associated with poorer survival (HR 2.8 and 1.76, respectively). Presenting with right-sided colon cancer, not resected primary tumor, WBC >10 × 10(9)/l, receiving less chemotherapy or no bevacizumab were all associated with inferior outcome. The all-wild-type subgroup (39.2%) reported the longest survival.

Conclusion: Extended mutational profile combined with clinical factors may impact on survival in mCRC.

Keywords: EGFR pathway; colorectal cancer; mutational profiling; prognostic factors.

PubMed Disclaimer

MeSH terms